Factoring in a more moderate earnings recovery; long-term view intact
11/04/24 -"The 2023 bottom line was materially below our expectations owing to the slower-than-expected recovery in profitability and higher interest expenses. Taking our cue from the 2023 trend, we have ..."
Pages
54
Language
English
Published on
11/04/24
You may also be interested by these reports :
06/11/26
Genmab’s sales missed expectations, but profitability significantly exceeded expectations. Growth was driven by contributions from most offerings, ...
06/11/26
Sanofi’s growth in recent years has been single-handedly driven by its cornerstone immunology treatment Dupixent, though there has been some support ...
06/11/26
Novonesis delivered an in-line Q3 26, with revenue and adjusted EBITDA marginally ahead of consensus. Food & Beverages (F&B) accelerated to 14%, ...
05/11/26
The Q3 qualitative update did not materially change the full-year outlook, as Branded’s strong momentum made up for the relative weakness in ...